Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

GxP Regulations in 2026: GMP, GLP, GDP, and Compliance Standards in Pharmaceutical Quality Systems

Explore GxP compliance frameworks and regulatory expectations across GMP, GLP and GDP systems, focusing on data integrity in pharma, ALCOA principles, audit readiness, and risk-based validation strategies aligned with FDA regulatory compliance pharma and EMA GMP guidelines.
  • Blog, Quality Management System
Pharmaceutical quality system workflow illustrating audit readiness in the pharmaceutical industry, emphasizing data integrity in pharma, ALCOA data integrity principles, GMP inspection findings, and risk based validation pharma approaches under EMA GMP guidelines and FDA regulatory compliance pharma.

Did You Miss the New Annex 1 Shift? : QA/QC Faces Real-Time Risk Pressure

At The Future of Bio/Pharmaceutical Analysis Virtual Summit 2026 held online on 23 June 2026, industry experts, regulators, and QA leaders discussed how Environmental Monitoring, endotoxin testing, and contamination control are shifting under Annex 1 and sustainability pressures. The session
  • News
Did You Miss the New Annex 1 Shift? : QA/QC Faces Real-Time Risk Pressure

FDA Leadership Crisis Shift ; Are You Tracking the Latest Regulatory Changes?

The U.S. Food and Drug Administration (FDA) has replaced acting leadership across its CDER and CBER review centers following recent senior departures in 2026, intensifying concerns over regulatory continuity. The shake-up comes amid broader institutional turnover in U.S. health agencies
  • News
FDA Leadership Crisis Shift ; Are You Tracking the Latest Regulatory Changes?

Pharma Regulations in 2026: Global Compliance Standards, GMP Requirements, and Regulatory Frameworks Explained

This article explains how global pharmaceutical regulations define GMP compliance expectations, inspection frameworks, and quality system maturity. It highlights regulatory inspection readiness pharma, data integrity systems, and compliance risk management shaping modern pharmaceutical regulatory environments and inspection outcomes.
  • Blog, Quality Management System
pharmaceutical manufacturing laboratory scene illustrating FDA EMA regulatory guidelines GMP compliance requirements pharma and regulatory inspection readiness pharma in quality system control environment

$15.2 Billion Deal Between Bristol Myers Squibb and Hengrui Pharma; GMP Compliance Alarm as Drug Development in China Accelerates

A strategic agreement between Bristol Myers Squibb (BMS) and Hengrui Pharma expands China’s role in early-stage drug development, covering 13 oncology, hematology, and immunology programs with up to $15.2 billion in potential value. Announced in 2026, the deal accelerates clinical
  • News
$15.2 Billion Deal Between Bristol Myers Squibb and Hengrui Pharma; GMP Compliance Alarm as Drug Development in China Accelerates

$166.4M Deal Between Zydus Lifesciences and Assertio Holdings; GMP Compliance Concerns Ripple Across Pharma Industry

Zydus Lifesciences will acquire Assertio Holdings in a $166.4m deal as the company continues expanding its specialty and biologics portfolio in regulated markets. The transaction, expected to close in Q2 2026, highlights the growing pace of pharma consolidation and could
  • News
Will Pharma Consolidation Improve Efficiency, Or Complicate GMP Compliance?

Is the Drug Shortage Crisis Intensifying? Hidden GMP Risks Across Pharma Supply Chains

Rising drug shortages are creating new compliance pressure across pharmaceutical supply chains and healthcare systems. In a recent discussion, Valerie Bandy from Tecsys warned that fragmented inventory visibility, delayed escalation, and growing reliance on manual workarounds are exposing hidden weaknesses
  • News
Is the Drug Shortage Crisis Intensifying? Hidden GMP Risks Across Pharma Supply Chains

India Pharma Expands Globally — Is Its Infrastructure Ready for Global Growth?

A PharmaVoice report published on May 13, 2026 by Kelly Bilodeau examines how India’s pharmaceutical industry is expanding globally through major acquisitions such as Sun Pharma’s $11.75 billion Organon deal. The article highlights growing ambition to compete with global leaders,
  • News
India Pharma Expands Globally — Is Its Infrastructure Ready for Global Growth?

MFN Policy Shock Reshapes Pharma Market; Europe Launches Drop, Withdrawals Rise

A GlobalData analysis published on March 25, 2026 reports that the US Most Favored Nation (MFN) Policy is already reshaping pharmaceutical markets in Europe. The study shows a significant drop in drug launches and a rise in withdrawals after the
  • News
MFN Policy Shock Reshapes Pharma Market; Europe Launches Drop, Withdrawals Rise

GLP-1 Boom Is Reshaping Pharma Manufacturing — Faster Speed, Higher GMP Risk

A recent PharmaTimes analysis highlights how GLP-1 drugs are reshaping pharmaceutical manufacturing under intense time-to-market pressure and rising investment in production capacity, particularly in the US. The report shows that fragmented systems, regulatory tightening, and AI adoption are increasing hidden
  • News
GLP-1 Boom Is Reshaping Pharma Manufacturing — Faster Speed, Higher GMP Risk